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ABSTRACT
Background
To study the potential association of antidepressant use and suicide at a population level, we
analyzed the associations between suicide rates and dispensing of the prototypic SSRI
antidepressant fluoxetine in the United States during the period 1960–2002.
Methods and Findings
Sources of data included Centers of Disease Control and US Census Bureau age-adjusted
suicide rates since 1960 and numbers of fluoxetine sales in the US, since its introduction in
1988. We conducted statistical analysis of age-adjusted population data and prescription
numbers. Suicide rates fluctuated between 12.2 and 13.7 per 100,000 for the entire population
from the early 1960s until 1988. Since then, suicide rates have gradually declined, with the
lowest value of 10.4 per 100,000 in 2000. This steady decline is significantly associated with
increased numbers of fluoxetine prescriptions dispensed from 2,469,000 in 1988 to 33,320,000
in 2002 (rs¼ 0.92; p , 0.001). Mathematical modeling of what suicide rates would have been
during the 1988–2002 period based on pre-1988 data indicates that since the introduction of
fluoxetine in 1988 through 2002 there has been a cumulative decrease in expected suicide
mortality of 33,600 individuals (posterior median, 95% Bayesian credible interval 22,400–
45,000).
Conclusions
The introduction of SSRIs in 1988 has been temporally associated with a substantial
reduction in the number of suicides. This effect may have been more apparent in the female
population, whom we postulate might have particularly benefited from SSRI treatment. While
these types of data cannot lead to conclusions on causality, we suggest here that in the context
of untreated depression being the major cause of suicide, antidepressant treatment could have
had a contributory role in the reduction of suicide rates in the period 1988–2002.
The Editors’ Summary of this article follows the references.
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Because of evidence made available in recent months, US
and UK regulatory agencies have been critically examining
suicidality and antidepressant use in children and adults. The
crucial point is whether antidepressants increase suicidality
over and above what is caused by the underlying disorders,
such as major depression. With such recent scrutiny of
antidepressants, particularly selective serotonin reuptake
inhibitors (SSRIs) and the US Food and Drug Administra-
tion-recommended ‘‘black box warning,’’ it becomes timely to
examine temporal trends in suicide and to study the potential
impact of antidepressants on mortality caused by self-harm.
This is a complex task because while on the one hand acute
antidepressant use has been associated with suicidality, but
untreated depression is also the major cause of suicide [1].
Therefore, two competing hypothesis exist. The ﬁrst is that
the acute effects of antidepressants can induce suicidality,
and the second is that by effectively treating depression,
antidepressants can reduce the rates of suicide.
Major depressive disorder is a common and complex
disorder of gene-environment interactions, for which there
is no curative treatment [2–4]. The disorder afﬂicts approx-
imately 10% of American men and 20% of American women
over their lifetimes. The point prevalence is in the range of
3% (2% in men, 4% in women) [5,6], but increases up to 10%
in the elderly [7,8]. Because the prevalence of depression is so
high, and treatment lasts several months to years, antide-
pressant pharmacotherapy is among the most frequently used
treatments in all of medical therapeutics.
Depression is itself the most prevalent cause of suicides [1],
and suicide is, in turn, still among the major causes of death.
According to the latest ﬁgures from the Centers for Disease
Control and Prevention (CDC), in the United States in 2002,
suicide was the eleventh leading cause of death (in 1998 it was
the eighth leading cause of death). When the data are
analyzed by age cohort, suicide is the ﬁfth leading cause of
death in the age group 5–14, the third leading cause of death
in the age group 15–24, and the fourth cause of death in the
age group 25–44 (Table 1) [9]. It has been estimated that
60%–70% of acutely depressed patients experience suicide
ideations [10]. It is universally agreed that depression
increases the risk for suicide. However, the extent of the risk
has been a subject of debate. The ﬁgure of lifetime risk for
suicide in patients with major depression had been com-
monly quoted as in the range of 10%–20% [10–12], based on
the study of hospitalized patients. However, recent studies
have examined other types of samples and found a much
lower risk, reported as 6% by Inskip et al. [13] based on a
meta-analysis, 3.4%–3.5% (7% in males and 1% in women)
based on gender and age-stratiﬁed calculations made on the
entire population [14,15], and 2.4% based on analysis of a
community sample in England [16]. An interesting meta-
analysis in which papers were stratiﬁed by type of presenta-
tion revealed that in patients hospitalized for suicidality the
lifetime prevalence of suicide was 8.6%; for affective disorder
patients hospitalized without speciﬁcation of suicidality, the
lifetime risk of suicide was 4.0%, and for mixed inpatient/
outpatient populations it was 2.2%; for the nonaffectively ill
population, it was less than 0.5% [17]. Depression appears to
be present in at least 50% of all suicides in adults [18,19]; in
children that rate has been reported to be in the range of
62%–76% [20,21].
The prototypic SSRI ﬂuoxetine was introduced in the
United States in 1988. Since then, ﬂuoxetine became the most
widely prescribed antidepressant drug in the world [22]. Since
its introduction, ﬂuoxetine has also been approved for use in
the treatment of patients with other disorders. It is currently
the only antidepressant that is FDA-approved for the treat-
ment of depression in children. Fluoxetine is a selective
inhibitor of serotonin reuptake and initially after admin-
istration it has limited effect on other neurotransmitters [23].
It is well absorbed after oral administration, with peak plasma
concentrations observed after 6–8 h. The parent compound,
ﬂuoxetine, has an elimination half-life of 1–4 d as compared
to the active metabolite, norﬂuoxetine, which has a half-life
of 7–10 d [24]. This extended half-life appeared to protect
against sporadic noncompliance and against the occurrence
of withdrawal phenomena [23].
Fluoxetine has been widely studied and described in the
scientiﬁc literature throughout the years and its use has been
reported in over 8,500 articles present in literature databases
(Medline and Embase databases until May 2003) [25]. All data
from the various meta-analyses conﬁrm that in the treatment
of patients with major depression, ﬂuoxetine has been as
effective as tricyclic antidepressants, and has shown to have a
distinctly more benign side effect proﬁle, be safer in
overdose, easier and simpler for patients to use and
physicians to prescribe, and to have lower rates of discontin-
uation [26]. Because of the fact that it was the ﬁrst SSRI
introduced to market and cumulatively the most prescribed,
we have used ﬂuoxetine as a prototypical SSRI and studied
trends in ﬂuoxetine prescription as a model for SSRI use
since 1988.
There are now two competing hypotheses on this impor-
tant clinical issue: (i) Antidepressants can trigger suicide, or
(ii) by treating depression, which is the largest cause of
suicide, antidepressants reduce overall suicide rates. We used
annual dispensing information on ﬂuoxetine and suicide
rates in the United States to address the question of whether
antidepressants by themselves are associated with increased
suicide numbers, or if they are linked to decreased suicide
rates.
Methods
Population Data
The total population data and distributions for the years
1960–2002 were obtained from the US Census Bureau.
Sources for the 1960–1999 period included Historical Na-
tional Population Estimates (July 1, 1900 to 2000) from the US
Census Bureau [27]. Data for Table 2 come from Current
Population Reports [28] and US Census Bureau National
Population Estimates web pages (http://www.census.gov/
popest/estimates.php). National population data for the years
1960–1979 cover the resident population plus Armed Forces
overseas. National population data for all other years cover
only the resident population. In addition, sources for the
2000–2002 period include the US Census Bureau’s American
FactFinder’s Data Sets: Population Estimates [29].
Suicide Data
The mortality data for this study were collected from
annual statistical ﬁles of the National Vital Statistics System
compiled by the CDC, which is a compilation of statistics
from all death certiﬁcates ﬁled in the 50 states and the
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Fluoxetine and Suicide RatesTable 1. Suicide as Cause of Death in Various Age Cohorts in the United States, 2002
Age Cohort Cause of Death
a Rank Number Death Rate
b
All ages All causes n/a
c 2,447,862 848.8
Diseases of the heart 1 695,754 214.3
Malignant neoplasms 2 558,847 193.8
Cerebrovascular diseases 3 163,010 56.5
Chronic lower respiratory diseases 4 125,500 43.5
Accidents (unintentional injuries) 5 102,303 35.5
Diabetes mellitus 6 73,119 25.4
Influenza and pneumonia 7 65,984 22.9
Alzheimer’s disease 8 58,785 20.4
Nephritis, nephrotic syndrome, and nephrosis 9 41,018 14.2
Septicemia 10 33,881 11.7
Suicide 11 30,646 10.6
5–14 All causes n/a
c 7,152 17.4
Accidents (unintentional injuries) 1 2,692 6.6
Malignant neoplasms 2 1,061 2.6
Congenital malformations, deformities, and chromosomal abnormalities 3 395 1.0
Assault (homicide) 4 342 0.8
Suicide 5 259 0.6
15–24 All causes n/a
c 33,009 81.3
Accidents (unintentional injuries) 1 15,026 37.0
Assault (homicide) 2 5,070 12.5
Suicide 3 3,932 9.7
25–44 All causes n/a
c 132,052 155.6
Accidents (unintentional injuries) 1 27,454 32.4
Malignant neoplasms 2 20,008 23.6
Diseases of the heart 3 16,155 19.0
Suicide 4 11,501 13.6
45–64 All causes n/a
c 425,412 637.9
Malignant neoplasms 1 143,416 215.1
Diseases of the heart 2 100,378 150.5
Accidents (unintentional injuries) 3 21,578 32.4
Cerebrovascular diseases 4 15,869 23.8
Diabetes mellitus 5 15,452 23.2
Chronic lower respiratory diseases 6 14,720 22.1
Chronic liver disease and cirrhosis 7 13,131 19.7
Suicide 8 9,517 14.3
Suicide is shown in bold font.
aBased on the International Classification of Diseases, Tenth Edition, 1992
bRates are per 100,000 population
cNot applicable. Source, see [9].
DOI: 10.1371/journal.pmed.0030190.t001
Table 2. Suicide Rates for the Total, Female, and Male Populations and Fluoxetine Prescription Data for the 1988–2002 Period
Year Fluoxetine Prescriptions
(Thousands)
Suicide Rate
(Total Population)
Suicide Rate
(Female Population)
Suicide Rate
(Male Population)
1988 2,469 12.5 5.1 21.2
1989 6,133 12.3 4.9 21.0
1990 10,655 12.5 4.8 21.5
1991 10,120 12.3 4.7 21.2
1992 11,443 12.1 4.7 20.6
1993 12,163 12.2 4.6 20.9
1994 16,427 12.1 4.5 20.7
1995 18,838 12.0 4.4 20.6
1996 20,705 11.7 4.3 20.0
1997 22,776 11.4 4.4 19.4
1998 24,757 11.3 4.3 19.2
1999 24,742 10.5 4.0 17.8
2000 24,344 10.4 4.0 17.7
2001 29,097 10.7 4.0 18.2
2002 33,320 10.9 4.2 18.4
All suicide rates are per 100,000.
DOI: 10.1371/journal.pmed.0030190.t002
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Fluoxetine and Suicide RatesDistrict of Columbia [30]. These data are based on the
implementation of a new population standard for age
standardization (age-adjustment) of death rates by the CDC.
The new standard is based on the year 2000 population and
has replaced the existing standard based on the 1940
population. This direct and indirect standardization and
statistical variability in age-adjusted death rates has provided
age-adjusted death rates that are substantially higher than
those based on the 1940 standards. Furthermore, the new
standards represent more accurate trends in age-adjusted
death rates for certain speciﬁc causes of death, such as
suicide, and have narrowed race differentials in age-adjusted
death rates [31].
In previous studies, crude death rates have been a widely
used measure of mortality. However, crude death rates are
inﬂuenced by the age composition of the population. As such,
comparisons of crude death rates over time or between
groups may be misleading if the populations that are being
compared differ in age composition. Age standardization is
one of the key tools used to control for the changing age
distribution of the population, and thereby to make mean-
ingful comparisons of vital rates over time and between
groups. This age-adjusted comparison is free from the
confounding effect of changing age distribution and there-
fore, better reﬂects the trend in US mortality [31]. The use of
age adjustment requires a ‘‘standard population,’’ which is a
set of arbitrary population weights. For this purpose, the
population age distribution for the year 2000 standards were
prepared by the US Bureau of the Census [32] and converted
by the National Center for Health Statistics to a standard
million population by dividing the age-speciﬁc populations
by the total population and multiplying by 1 million.
Fluoxetine Prescription Data
We obtained the estimates for the prescription trends and
dispensed numbers for ﬂuoxetine from IMS Health USA, the
leading international provider of data on drug use to the
pharmaceutical and healthcare industries. The data for
ﬂuoxetine were extracted from their extensive National
Prescription Audit database in Philadelphia, which provides
information based on dispensed prescriptions from retail,
mail service, and LTC pharmacies. National Prescription
Audit data are projected to a national level from a sample of
over 20,000 retail pharmacies. These data are representative
of the total dispensed prescriptions for ﬂuoxetine from when
it was introduced to the market in 1988–2002. The dispensed
numbers were reported in thousands for the formulations
Prozac (SMRY 0188 LLY), Prozac Weekly (SMRY 0301 LLY),
and ﬂuoxetine-HCl (SMRY 0000 USA). The ﬂuoxetine-HCl
generic formulation and Prozac Weekly formulation were
ﬁrst introduced in 2001. The numbers for the Prozac Weekly
regimen were multiplied by seven in order to account for the
single weekly dispensation of this type of formulation and to
adjust for the dispensation numbers in correlation with rest
of the daily-dispensed data.
The ﬂuoxetine data on the percent of dispensation for
speciﬁc disorders were obtained independently of the yearly
dispensed data from IMS Health for the period of 2002–2004,
with 2002 being the ﬁrst year that they kept track of this type
of information in their database. These data provided a
speciﬁc list of disorders that ﬂuoxetine was prescribed for
and the relative percentage of dispensation of ﬂuoxetine in
the given year for these disorders. See Table 2 for suicide
rates and ﬂuoxetine prescription data for the period 1988–
2002.
Statistical Analyses and Modeling Methods
We ﬁrst examined the association between ﬂuoxetine
prescription numbers and suicide rates in 1988–2002 using
Spearman’s rank correlation test. This nonparametric test is
more robust than Pearson’s correlation coefﬁcient, as the test
does not assume that the data come from a bivariate normal
distribution.
To predict suicide mortality in 1988–2002, assuming that
pre-1988 trends had been maintained and accurately esti-
mated the cumulative decrease in deaths attributable to
ﬂuoxetine, we developed a time-series regression model. The
model assumes that the underlying time dynamics in age-
adjusted suicide rates are described by two effects. The ﬁrst is
an autoregressive (AR) random walk process between 1960
and 2002 and the second is a linear regression model that
incorporates ﬂuoxetine prescription numbers as a covariate
from 1988 onward. AR processes are standardly employed to
capture the dependence between observations in randomly
varying time series and to utilize this dependence to make
forward predictions [33]. We selected the appropriate order
of the AR process and of the ﬂuoxetine effect via model
selection, leading to a ﬁrst-order AR process and linear
ﬂuoxetine effect. Under this model, let Yt equal the age-
adjusted suicide rate (measure in percent of deaths) and Xt
equal the number of ﬂuoxetine prescriptions (measured in
millions) at time t.
Yt ¼ lt þ bXt þ et ð1Þ
and
lt ¼ qmt 1 þ mt ð2Þ
where b is the ﬂuoxetine effect size, q is the AR lag-1
parameter, and et and vt are independent Gaussian white
noise.
We ﬁt this AR regression model in a Bayesian framework
[34], assuming diffuse priors on model parameters. Unlike
likelihood-based estimation procedures, Bayesian approaches
do not require a stationarity constraint ( 1   q   1) on the
underlying random walk process [35]. The assumption of
stationarity in this form of regression model would imply that
any long-term drift of suicide rates resulted from the additive
covariate Xt and were not generated by the AR process. Such
an assumption would lead to an unfair test of the inﬂuence of
ﬂuoxetine on suicide rates if these rates were naturally
decreasing over time. Rather, we opted for a potentially
nonstationary model. As a consequence, identiﬁability be-
tween the covariate effect and AR coefﬁcients may be
compromised [36]. We guarded against this shortcoming by
employing suicide rate observations that extend as far back in
the past as possible before the introduction of SSRIs. These
early time points yield information in our model solely about
the underlying random walk characterized by q, separating it
from a potential ﬂuoxetine effect later in time estimated by b.
To examine potential differences in response to ﬂuoxetine
across female and male populations, we reﬁtted our time-
series regression model to suicide rates stratiﬁed by gender.
In this model, we assumed that the AR process was the same
for both females and males such that they shared a common
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Fluoxetine and Suicide RatesAR lag-1 parameter q; however, females and males may have
different ﬂuoxetine effect sizes, and D represents this differ-
ence. This approach assumes that female and male prescrip-
tion rates were the same.
Results
Percent of Fluoxetine Dispensed for Depression
By examining the data on ﬂuoxetine dispensation for the
speciﬁc associated disorders, we found, as expected, that for
the period 2002–2004, depression was the primary reason
that these drugs were dispensed. Using this sample time
period, as an indicator of relative use of these drugs, we found
that for the period 2002–2004, major depression was the
reason for 72.1% of all ﬂuoxetine that was dispensed, with the
other 27.9% dispensed for the following disorders in order of
frequency: anxiety (6.2%), obsessive-compulsive disorder
(5.7%), schizophrenia (2.2%), stress (2.0%), premenstrual
syndrome (1.0%), phobias (0.8%), eating disorders (1.0%),
and all others unclassiﬁed (8.8%).
Trends in Suicide and Fluoxetine Dispensing
Suicide rates had been ﬂuctuating between 12.2% and
13.7% per 100,000 for the entire population from the early
1960s until the late 1980s, when they showed a gradual
decline below 12%, with the lowest value of 10.4% in 2000
(Figure 1A and Table 2). For the male population, the rates of
suicide had been higher, ﬂuctuating between 21.9% and
19.1% in the pre-SSRI era, with a gradual decline since the
late 1980s to their lowest value of 17.7% in 2000 (Figure 2B
and Table 2). Likewise, suicide rates in the female population
had ﬂuctuated between 7.6% and 5.2% in the same period,
showing a signiﬁcant decline in the post-SSRI era at levels
below the 5% mark in 1989, and they remained at 4% in the
1999–2001 period (Figure 2A and Table 2).
Association between Suicide and Fluoxetine Dispensing
The steady decline in suicide rates for both men and
women is associated with an increasing number of ﬂuoxetine
prescriptions from 2,469,000 in 1988 to 33,320,000 in 2002. A
cross-correlation analysis of ﬂuoxetine use and suicide rates
in the period 1988–2002 shows a signiﬁcant negative
correlation: rs ¼  0.92, p , 0.001 (Figure 1C).
Modeling Suicide Rates in 1988–2002 Based on Pre-1988
Trends
Under our time-series regression model, we estimate that
the ﬂuoxetine effect size b is  4.7 (posterior median; 95%
Bayesian credible interval [BCI], 6.2 to 3.1) per 100 million
prescriptions. Since the entire 95% BCI falls below zero, the
data offer strong support for the hypothesis that ﬂuoxetine
decreases suicide rates. We also estimated that q¼1.0 (0.52 to
2.6), suggesting that nonstationary drift not caused by
increasing ﬂuoxetine usage remains in the underlying suicide
rate trend, supporting the use of a nonstationary model.
In Figure 1B, the model estimates and predictions of age-
adjusted suicide rates are plotted over time. Shown in black
are posterior median and 95% BCI estimates incorporating
the observed ﬂuoxetine prescription levels for the years 1960
through 2002. In red, the plot predictions of suicide rates are
superimposed on the number of ﬂuoxetine prescriptions in
ﬁxed to 0 from 1988 onward. Beginning at year 1993, the BCIs
with and without ﬂuoxetine diverge, reinforcing the con-
clusion that ﬂuoxetine is signiﬁcantly decreasing suicide
rates, even after controlling for potential drift in the
underlying random walk. In terms of this drift, suicide rates
between 1998 and 2000 decreased substantially more than
would be predicted by increasing ﬂuoxetine usage alone and
are again seen to raise post 2000. It is unknown what is
causing these additional dynamics.
Figure 2C and 2D plot the model estimates and predictions
stratiﬁed by gender. Distances between observed suicide rates
Figure 1. Age-Adjusted Suicide Rates at the Population Level
(A) Age-adjusted suicide rates (per 100,000) for the total population from
1960 to 2002 and fluoxetine prescribed numbers (in millions) from 1988
to 2002
(B) Age-adjusted suicide rate predictions for the total population. The
solid lines trace out the posterior median model predictions and the
dashed lines depict the 95% Bayesian credible intervals. The top red line
depicts the predicted suicide rates without fluoxetine and the bottom
black line represents the actual rates with fluoxetine.
(C) This figure demonstrates the linear relationship between suicide rates
and fluoxetine prescription numbers.
DOI: 10.1371/journal.pmed.0030190.g001
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than for males. This observation is also reﬂected in our
estimate of the differential ﬂuoxetine effect size D. The
posterior median estimate of q is 2.7 and its 95% BCI covers
 6.4 to 0.92, with approximately 93% of its posterior mass
lying less than zero. The zero point represents no differences
between females and males. Several studies have shown that
women are prescribed more antidepressants than men [37];
however, the data we utilized are not available grouped by
gender throughout the study period. Therefore, our results
suggesting that ﬂuoxetine is more strongly associated with
decreasing suicide rates in females than in males have to be
interpreted with considerable caution.
Using the total number of observed suicide deaths (with
ﬂuoxetine) per year and our time-series model, we estimated
the approximate number of additional deaths we might have
expected if pre-1988 trends were maintained. If the hypoth-
esis that ﬂuoxetine decreases suicide rates were to be
accepted, then taking the difference between the predicted
and actual suicide deaths would estimate the number of
suicides that were presumably prevented by SSRIs such as
ﬂuoxetine. Figure 3 shows these estimates for each year
(posterior median prediction with 95% BCIs). Summing of
these values in the period 1988–2002 would, on that basis,
result in an estimation that SSRIs may have saved 33,600
(22,400–45,000) lives since their introduction.
Discussion
A debate on the association of antidepressants and
suicidality has intensiﬁed in recent months. Two possibilities
exist: either antidepressants increase suicidality or by
effectively treating depression, which is the principal cause
of suicide, antidepressants reduce suicidality. It is important
to note that there is a substantial difference between
suicidality, which is deﬁned by feelings, thoughts, and
behaviors related to suicide, and actual deaths caused by
suicide. While suicidality is alarming, we believe that the
actual impact of antidepressants could best be assessed at the
public health level by a study of actual numbers of completed
suicides.
Grunebaum et al. [38] previously reported a temporal
association between increased use of SSRIs with decreased
rates of suicide in the US in 1985–1999. In concordance with
the ﬁndings of that study, we found here a highly signiﬁcant
negative correlation between ﬂuoxetine dispensing, which is
Figure 2. Age-Adjusted Suicide Rates by Sex
(A and B) Suicide rates (per 100,000) for the total female (A) and male (B) populations from 1960–2002.
(C and D) Age-adjusted suicide rate predictions for the female (C) and male (D) populations. Solid lines trace out the posterior median model
predictions and the dashed lines depict the 95% Bayesian credible intervals. The top red line depicts the predicted suicide rates without fluoxetine and
the bottom black line represents the current rates with fluoxetine.
DOI: 10.1371/journal.pmed.0030190.g002
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Fluoxetine and Suicide Ratespredominantly used to treat major depression, and US
suicide rates in the period 1988–2002. We also modeled
suicide rates in the period post-1988, using historical data to
better represent the underlying random walk that rates take
over time. While overall mortality rates have not decreased
since 1988, suicide mortality has decreased steadily since
1988. Our modeling analysis shows that if pre-1988 trends
(pre-SSRI era) were extrapolated through to 2002, mortality
numbers by suicide would have been higher by approximately
33,600 cases. This could lead one to hypothesize that SSRIs
have saved approximately 33,600 lives in the United States
alone during this period.
Our modeling results also suggest that ﬂuoxetine has been
associated with a greater decrease in suicide rates in females
than in males. This ﬁnding is based on a model that assumes
that affected females and males are equally likely to be
prescribed and take ﬂuoxetine. However, further studies are
warranted to examine and further deﬁne this modeling
assumption and to further investigate the prescription rates
for males and females, including compliance and follow-up
issues between the two sexes. If females were more likely to
seek treatment for depression and follow through with the
drug regimens and therapy course than males, they would
beneﬁt more from SSRI use. This might explain the greater
demonstrated drop in rates of suicide for the female
population. Unfortunately it is not possible to look at
ﬂuoxetine dispensing by sex, as such data are not available
from IMS or from other sources. An alternative and not
mutually exclusive explanation could be based on the fact
that antidepressants are frequently used in overdose as
method for suicide attempts. A shift away from older, far
more lethal in overdose, tricyclic antidepressants to SSRIs
could therefore have some impact on the reduction of suicide
rates. This impact could be greater in females, in whom
intoxication is by far the most often chosen method for
suicide attempts.
Similar to what has happened in the US, in many other
developed countries the numbers of prescriptions for SSRIs
such as ﬂuoxetine have increased steeply since their advent in
the late 1980s and early 1990s. A study looking at changes in
suicide rates for the Australian population and exposure to
SSRIs for the 1991–2000 period also found a signiﬁcant
association between the two. They found that the higher the
population’s exposure to antidepressants, the larger was the
decline in rate of suicide. Most signiﬁcantly, this was
demonstrated in the older age groups, in which rates of
suicide decreased substantially in association with exposure
to SSRIs [39]. Similarly, in Sweden, which has a higher total
population suicide rate, prescription rates for SSRIs in-
creased dramatically in the early 1990s, and the rates of
suicide showed an inverse relationship to the rates of
antidepressant prescriptions in most age and sex groups
[40]. In another study in Sweden, which examined ofﬁcial
mortality statistic data for 1977–1997 and data on antide-
pressant use from surveys of sales to pharmacies, they found
that suicide rates in general declined over the whole study
period, but the rate of decline accelerated after the
introduction of SSRIs in the early1990s [41]. In yet another
European study in Hungary for the period of 1984–1998,
antidepressant prescription rates rose steeply after the
introduction of SSRIs in the early 1990s. With this, the rates
of suicide proportionally declined, despite steep increases in
unemployment and per capita alcohol consumption [42].
Recent studies on antidepressant-related suicidality [43–45]
did not address the effects of antidepressants in the overall
population over the long term and examined only the acute
outcome measured for the treating drugs in question. In
contrast, we looked at the possible impact of SSRIs over a 14-
y period and the resulting cumulative overall effect on suicide
rates over that period. In the present study we tried to
address the issue of whether acute and transitory thoughts
and feelings of suicide related to antidepressant treatment
were in the long term associated with increased suicide rates,
or if the opposite might be occurring: by effectively treating
depression, antidepressants could be associated in a reduc-
tion of actual suicide rates.
Our results indicate a temporal association between the
introduction of ﬂuoxetine and increased dispensing patterns
and decreased rates of suicide, but they do not establish a
mechanistic cause. When the competing hypotheses (i) that
antidepressants can trigger suicide, or (ii) that by treating
depression antidepressants reduce suicide rates, are exam-
ined in light of our results, it is logical to refute the concept
that on a population level ﬂuoxetine dispensing is associated
with increased suicide, because not only did suicide rates start
to decrease after ﬂuoxetine came to market, but we also show
here a highly signiﬁcant negative correlation between
ﬂuoxetine dispensing and suicide rates. If the opposing
hypothesis (i) were true, then we would have expected to ﬁnd
an overall rise in the rates of suicide after the introduction of
SSRIs or at least not a drop in the rates. Moreover, according
to our modeling, if pre-1988 (and hence pre-ﬂuoxetine)
suicide trends had persisted to the end of the study period,
the number of suicides would have been in the range of
33,600 higher in cumulative terms.
A limitation of this work is that the analysis was across
combined age groups. This could not be helped for the
prescription data, which is not categorized by age, but the
suicide data are available by age (and by sex). Gunnell and
Ashby [46] found that there were very different trends in
suicide across different age groups, which could complicate
the interpretation of our analyses. In the absence of
prescription data by gender and age across the entire study
period, we felt it would less problematic to simply analyze the
data by sex of suicide victims than to also introduce another
variable that would lead to complex stratiﬁcations by various
Figure 3. Estimated Number of Lives Saved Since 1988–2002 with the
Advent of SSRIs
Data are shown as a posterior median prediction with 95% Bayesian
credible intervals.
DOI: 10.1371/journal.pmed.0030190.g003
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prescription data by age group.
In this study we used ﬂuoxetine as an index of SSRI use. It
was the ﬁrst and most widely used of this class of drugs.
Would our results have been different if we had included data
on all SSRI prescriptions in the United States since 1988? If
we assume that all SSRIs are equivalently effective and group
them together, then the structure of our Bayesian model does
not change. What does change is that the number of
prescriptions, particularly in recent years, would be higher
than reported in this analysis. Furthermore, given our
hypothesis, we would expect that this correlation would only
increase with a larger number of prescribed SSRIs other than
ﬂuoxetine. In Figure 1C, this modiﬁcation would stretch the
far right values further to the right, suggesting a stronger
correlation between antidepressant use and decreased suicide
numbers. Under the equivalency assumption and by restrict-
ing our analysis to ﬂuoxetine, we present here a conservative
estimate of the strength of the negative correlation between
antidepressant use and completed suicides. Natural exten-
sions to the linear regression portion of our Bayesian model
exist to test for differences between the effectiveness of
various SSRIs at the population level.
As elegantly stated by Gibbons and colleagues [47], it
should be noted that causal associations cannot be established
with this type of observational data. Moreover, we would like
to caution that this type of data and study is limited by its
large scale, and does not examine speciﬁc effects on smaller
parts of this population. Therefore, although SSRIs would
seem likely to have signiﬁcant public health beneﬁts in
decreasing suicide rates, with this type of data we cannot
conﬁdently rule out the possibility that ﬂuoxetine treatment
is associated with an increased risk of suicide in a smaller
group of individuals. However, we can conclude that, for the
entire US population, a direct, inverse correlation exists
between suicide rates and ﬂuoxetine, and that treatment with
ﬂuoxetine (or possibly all SSRIs) for depression and other
mood disorders may have contributed to the prevention of as
many as 33,600 suicides since the drug was introduced.
Similar to our results in adults, a recent study by Weller et
al. [48] in the US, showed that the past decade has seen a
signiﬁcant drop in the rates of adolescent suicide, which
coincided with the onset of the use of these SSRIs. Those
authors cautioned that a reduction in the use of SSRIs in
children and adolescents should therefore be considered very
carefully.
Our results support the hypothesis that at a population
level, SSRI treatment is temporally associated with decreased
suicide rates, presumably due to effective treatment of major
depression, which when untreated is the principal cause of
suicide. If this conclusion is correct, decreased rates of
antidepressant dispensing could have the opposite effect of
leading to increased suicide rates. Current trends of
decreased antidepressant sales are therefore worrisome. We
suggest here that public health efforts to address suicidality
caused by acute antidepressant treatment should be tem-
pered by an awareness of our data showing that at the
population level antidepressant use is highly negatively
associated with actual deaths by suicide in the long term.
Consequently, limiting the use of antidepressants may
eventually result in increased deaths by suicide. While our
study was based on the prototypical SSRI ﬂuoxetine and this
type of study is limited, future studies could further expand
on our results to examine other SSRIs and data from other
countries, both developed and developing. Finally, although
the current issue concerning antidepressants and suicidality
requires further examination, we believe that many more
lives have been saved than lost since the advent of these drugs.
Acknowledgments
Author contributions. MSM, MAS, MLW, and JL designed the study.
MAS and JL analyzed the data. MSM, MAS, MLW and JL contributed
to writing the paper. &
References
1. Isacsson G, Holmgren P, Druid H, Bergman U (1999) Psychotropics and
suicide prevention. Implications from toxicological screening of 5281
suicides in Sweden 1992–1994. Br J Psychiatry 174: 259–265.
2. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, et al. (1996)
Cross-national epidemiology of major depression and bipolar disorder.
JAMA 276: 293–299.
3. Wong ML, Licinio J (2005) Biology of depression: From novel insights to
therapeutic strategies. Weinheim (Germany): Wiley-VCH. 1092 p.
4. Wong ML, Licinio J (2004) From monoamines to genomic targets: A
paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3:
136–151.
5. Wong ML, Licinio J (2001) Research and treatment approaches to
depression. Nature Rev Neurosci 2: 343–351.
6. Wu LT, Anthony JC (2000) The estimated rate of depressed mood in US
adults: Recent evidence for a peak in later life. J Affect Disord 60: 159–171.
7. Roberts RE, Kaplan GA, Shema SJ, Strawbridge WJ (1997) Does growing old
increase the risk for depression? Am J Psychiatry 154: 1384–1390.
8. Roberts RE, Kaplan GA, Shema SJ, Strawbridge WJ (1997) Prevalence and
correlates of depression in an aging cohort: The Alameda County Study. J
Gerontol B Psychol Sci Soc Sci 52: S252–S258.
9. Kochanek KD, Smith BL (2004) Deaths: Preliminary data for 2002. Natl Vial
Stat Rep 52: 1–47.
10. Moller HJ (2003) Suicide, suicidality and suicide prevention in affective
disorders. Acta Psychiatr Scand Suppl: 73–80.
11. Goodwin FK, Jamison KR (1990) Manic-depressive illness. New York:
University Press. 938 p.
12. Guze SB, Robins E (1970) Suicide and primary affective disorders. Br J
Psychiatry 117: 437–438.
13. Inskip HM, Harris EC, Barraclough B (1998) Lifetime risk of suicide for
affective disorder, alcoholism and schizophrenia. Br J Psychiatry 172: 35–
37.
14. Blair-West GW, Mellsop GW, Eyeson-Annan ML (1997) Down-rating
lifetime suicide risk in major depression. Acta Psychiatr Scand 95: 259–263.
15. Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML (1999)
Lifetime suicide risk in major depression: Sex and age determinants. J
Affect Disord 55: 171–178.
16. Boardman AP, Healy D (2001) Modelling suicide risk in affective disorders.
Eur Psychiatry 16: 400–405.
17. Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: A
reexamination. Am J Psychiatry 157: 1925–1932.
18. Henriksson MM, Aro HM, Marttunen MJ, Heikkinen ME, Isometsa ET, et al.
(1993) Mental disorders and comorbidity in suicide. Am J Psychiatry 150:
935–940.
19. Balazs J, Lecrubier Y, Csiszer N, Kosztak J, Bitter L (2003) Prevalence and
comorbidity of affective disorders in persons making suicide attempts in
Hungary: Importance of the ﬁrst depressive episodes and of bipolar II
diagnoses. J Affect Disord 76: 113–119.
20. Shaﬁi M, Steltz-Lenarsky J, Derrick AM, Beckner C, Whittinghill JR (1988)
Comorbidity of mental disorders in the post-mortem diagnosis of
completed suicide in children and adolescents. J Affect Disord 15: 227–233.
21. Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, et al. (1996)
Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry
53: 339–348.
22. Wong DT, Bymaster FP, Engleman EA (1995) Prozac (ﬂuoxetine, Lilly
110140), the ﬁrst selective serotonin uptake inhibitor and an antidepres-
sant drug: Twenty years since its ﬁrst publication. Life Sci 57: 411–441.
23. Guze BH, Gitlin M (1994) New antidepressants and the treatment of
depression. J Fam Pract 38: 49–57.
24. American Medical Association (1992) Psychopharmacologic drugs. In:
Drugs used in mood disorders. Drug Evaluation Subscription 1: 32.
25. Rossi A, Barraco A, Donda P (2004) Fluoxetine: A review on evidence based
medicine. Ann Gen Hosp Psychiatry 3: 2.
26. Stokes PE, Holtz A (1997) Fluoxetine tenth anniversary update: The
progress continues. Clin Ther 19: 1135–1250.
27. US Census Bureau (2002) Demographic Trends in the 20th Century
PLoS Medicine | www.plosmedicine.org June 2006 | Volume 3 | Issue 6 | e190 0823
Fluoxetine and Suicide Rates(Census 2000 Special Reports). Available: http://www.census.gov/prod/
2002pubs/censr-4.pdf. Accessed 9 May 2006.
28. US Census Bureau (2005) Population estimates. Available: http://www.cen-
sus.gov/popest/estimates.php. Accessed 9 May 2006.
29. US Census Bureau (2005) . US Census Bureau (2005) American FactFinder:
Population Estimates Program. Available: http://www.factﬁnder.census.gov/
home/saff/main.html?_lang¼en. Accessed 9 May 2006.
30. National Center for Health Statistics (1998) Technical appendix. Vital
statistics of the United States, 1994, volume II, mortality, part A.
Washington (D. C.): Public Health Service. Available: http://www.cdc.gov/
nchsw. Accessed 1 September 2005.
31. Anderson RN, Rosenberg HM (1998) Age standardization of death rates:
Implementation of the Year 2000 Standard. Natl Vital Stat Rep 47: 1–16.
32. Day JC (1996) U.S. Bureau of the Census. Population projections of the
United States by age, sex, race, and Hispanic origin: 1995 to 2050. Current
population reports; series P-25, number 1130. Washington (D. C.): U.S.
Government Printing Ofﬁce.
33. Zellner A (1996) An introduction to Bayesian inference in econometrics.
New York: Wiley.
34. Bayes CS (1993) Regression with autoregressive errors: A Gibbs sampling
approach. J Econom 58: 275–294.
35. Broemeling LD, Cook P (1993) Bayesian estimation of the means of the AR
process. J Appl Stat 20: 25–39.
36. Zellner A, Tiao G (1964) Bayesian analysis of the regression model with
autocorrelated errors. J Am Stat Assoc 59: 763–778.
37. Sleath B, Shih YC (2003) Sociological inﬂuences on antidepressant
prescribing. Soc Sci Med 56: 1335–1344.
38. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ (2004) Antidepres-
sants and suicide risk in the United States, 1985–1999. J Clin Psychiatry 65:
1456–1462.
39. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003)
Association between antidepressant prescribing and suicide in Australia,
1991–2000: Trend analysis. BMJ 326: 1008.
40. Isacsson G (2000) Suicide prevention—A medical breakthrough? Acta
Psychiatr Scand 102: 113–117.
41. Carlsten A, Waern M, Ekedahl A, Ranstam J (2001) Antidepressant
medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 10:
525–530.
42. Rihmer Z (2001) Can better recognition and treatment of depression
reduce suicide rates? A brief review. Eur Psychiatry 16: 406–409.
43. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B
(2005) Association between suicide attempts and selective serotonin
reuptake inhibitors: Systematic review of randomised controlled trials.
BMJ 330: 396–399.
44. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S,
Gunnell D (2005) Antidepressant treatment and the risk of fatal and non-
fatal self harm in ﬁrst episode depression: Nested case-control study. BMJ
330: 389–393.
45. Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake
inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company
data from placebo controlled, randomised controlled trials submitted to
the MHRA’s safety review. BMJ 330: 385–388.
46. Gunnell D, Ashby D (2004) Antidepressants and suicide: What is the
balance of beneﬁt and harm. BMJ 329: 34–38.
47. Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005) The relationship between
antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:
165–172.
48. Weller EB, Tucker S, Weller RA (2005) The selective serotonin reuptake
inhibitors controversy in the treatment of depression in children. Curr
Psychiatry Rep 7: 87–90.
Editors’ Summary
Background. Depression is very common. For example, in the US, an
estimated 10% of men and 20% of women will suffer from major
depression at some stage in their lives. One way of treating the condition
is with drugs. Several types of antidepressant drugs are available, and in
many countries they are among the most commonly prescribed
medicines. However, all antidepressants have side effects.
One family of antidepressants, called selective serotonin uptake
inhibitors (SSRIs), was introduced in the late 1980s. The name of these
drugs comes from their effect, which is to prevent the removal
(reuptake) from the nerve endings of one type of chemical (serotonin)
that is important for transmitting nerve impulses between brain cells.
SSRIs are claimed to be more effective and to have fewer side effects
than older antidepressants, and many brands of SSRI are now on the
market. However, in recent years there have been claims that some
people taking SSRIs have committed suicide as a result of the drugs.
Whether the SSRIs are the cause of the suicide is hard to know, because
people who are depressed do sometimes feel like killing themselves; so if
a depressed person taking an SSRI commits suicide, it is hard to tell
whether this is a result of the depression or a side effect of the treatment
(the SSRI). The drug regulatory authorities in some countries are now
carefully studying the issue of suicides and antidepressant use, both in
adults and in children. The US Federal Drug Administration has issued
what it calls a ‘‘black box warning’’ on the use of these drugs.
Why Was This Study Done? The researchers wanted to discover
whether the number of suicides in the US had increased or decreased
since treatment with the first widely used SSRI (fluoxetine, also known as
Prozac) began in 1988. Any difference in the number of suicides found
before and after that date would not necessarily be the result of the
introduction of this antidepressant, or other SSRIs, but the information
would provide helpful information about the effects of these drugs.
What Did the Researchers Do and Find? They looked at annual suicide
rates between 1960 and 1988 and compared them with annual rates in
the period 1988 to 2002. They used several sources of data, including the
Centers of Disease Control and the US Census Bureau. The researchers
found that from the early 1960s until 1988, in the entire US population,
between 12.2 and 13.7 people in every 100,000 committed suicide each
year. After that time, the numbers of suicides gradually declined, with
the lowest figure (10.4 people per 100,000) reached in 2000. The
researchers did mathematical tests, which demonstrated that the steady
decline was statistically associated with the increased number of
fluoxetine prescriptions—that is, the more prescriptions there were,
the fewer suicides there were. (There were around two-and-a-half million
prescriptions of the drug in 1988, increasing to over 33 million in 2002.)
What Do These Findings Mean? In all scientific research, it is an
important principle that finding an association between two events does
not prove that one caused the other to occur. However, the authors of
this paper suggest that the use of this drug could have contributed to
the reduction of suicide rates in the US in the period 1988 to 2002.
Several other SSRIs are also now in common use, but they were not
considered in this study, nor were other antidepressants, or other
treatments for depression.
Additional Information. As depression is such a common condition—
and because there are so many ways of treating it, including counseling
and psychotherapy—there are many Web sites devoted to the subject.
We have given a small selection below. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.1371/journal.
pmed.0030190.
  From the American Academy of Family Physicians (AAFP), general
advice on depression
  Also from the AAFP, advice specifically about antidepressant drugs
  MedlinePlus brings together authoritative information about
depression from the US National Library of Medicine, National
Institutes of Health, and other government agencies and health-
related organizations
  Health pages of the BBC on depression
  Information about depression from other UK health advice sites:
Patient UK and NetDoctor.co.uk
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